Skip to main content
TipRanks
Go Ultimate75% OFF

Gufic Biosciences Limited (GUFICBIO) AI Stock Analysis

0 Followers
IN:GUFICBIO

Gufic Biosciences Limited

(NSE:GUFICBIO)

Select Model
Rating:58Neutral
Price Target:INR 505.00▲(7.09% Upside)
Action:reiterated
Date:09/30/26

The score is held back primarily by weak and volatile cash flows (sharp FY2026 operating cash flow decline and negative free cash flow) and a high P/E valuation. Offsetting these risks, the technical setup is positive with the stock trading above major moving averages and moderate momentum readings.

Positive Factors
Specialty Formulations PlatformThe company’s focus on injectable, lyophilized, critical-care and specialty formulations creates a differentiated operating platform within pharmaceuticals. Sterile manufacturing capabilities and branded-generics exposure can support product breadth, customer relevance and durable participation across domestic and international markets.
Negative Factors
Weak Cash ConversionThe sharp operating-cash-flow decline and negative free cash flow are significant weaknesses because reported earnings are not translating into internally generated funds. Persistent volatility in operating and free cash flow could constrain reinvestment, debt reduction and the company’s ability to absorb operating setbacks.

Gufic Biosciences Limited (GUFICBIO) vs. iShares MSCI India ETF (INDA)

-20%-10%0%10%20%30%40%50%IN:GUFICBIO+43.06%INDA-5.86%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
INR 42.18B
Dividend Yield
0.02%
Average Volume (3M)
6,546
Price to Earnings (P/E)
64.2
Beta (1Y)
0.68
Revenue Growth
16.70%
EPS Growth
18.73%
Country
India
Employees
1,491
Sector
General
Sector Strength
55
Industry
Drug Manufacturers - Specialty & Generic

Gufic Biosciences Limited Business Overview & Revenue Model

Company Description

Gufic Biosciences Limited is an Indian enterprise dedicated to the manufacturing and marketing of active pharmaceutical ingredients (APIs), generic medications, and related support services. The company's API and bulk drug offerings include antifunga...

Gufic Biosciences Limited Financial Statement Overview

Summary

Operating performance is decent (FY2026 gross margin ~36%, operating margin ~12.8%) and leverage is manageable (debt-to-equity ~0.61), but cash generation is a major weakness: operating cash flow fell sharply (~132M vs ~1.03B prior year) and free cash flow turned negative (FY2026 -180M). Margins and net income also declined in FY2026, reducing overall statement quality.

Income Statement

70Positive

Balance Sheet

68Positive

Cash Flow

34Negative
Financial statement breakdown
BreakdownTTMMar 2026Mar 2025Mar 2024Mar 2023Mar 2022
Income Statement
Total Revenue9.81B9.44B8.20B8.07B6.91B7.79B
Gross Profit4.52B3.40B2.97B4.07B3.51B3.56B
EBITDA1.66B1.54B1.38B1.48B1.37B1.50B
Net Income734.57M642.15M696.50M861.36M797.05M958.40M
Balance Sheet
Total Assets013.42B11.69B10.93B8.61B5.21B
Cash, Cash Equivalents and Short-Term Investments621.86M762.17M290.22M11.37M286.02M116.08M
Total Debt04.05B3.36B3.33B3.34B643.87M
Total Liabilities-6.65B6.77B5.68B5.60B5.13B2.52B
Stockholders Equity6.65B6.65B6.01B5.33B3.48B2.69B
Cash Flow
Free Cash Flow434.82M-180.11M270.96M-1.20B-2.14B187.86M
Operating Cash Flow591.15M131.71M1.03B-74.57M-265.87M1.06B
Investing Cash Flow-152.90M-319.73M-717.09M-1.02B-1.91B-945.89M
Financing Cash Flow150.53M652.67M-163.26M823.81M2.34B-62.44M

Gufic Biosciences Limited Technical Analysis

Technical Analysis SentimentPositive
Last Price471.55

Price Trends

50DMA426.40Positive
100DMA412.02Positive
200DMA358.63Positive

Market Momentum

MACD13.98Negative
RSI64.83Neutral
STOCH79.24Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:GUFICBIO, the sentiment is Positive. The current price of 471.55 is above the 20-day moving average (MA) of 425.38, above the 50-day MA of 426.40, and above the 200-day MA of 358.63, indicating a bullish trend. The MACD of 13.98 indicates Negative momentum. The RSI at 64.83 is Neutral, neither overbought nor oversold. The STOCH value of 79.24 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:GUFICBIO.

Gufic Biosciences Limited Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

IN:GUFICBIO against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
IN:BLISSGVSIN:BLISSGVS65NeutralINR 71.56B44.55―0.22%24.87%46.37%
IN:GUFICBIOIN:GUFICBIO58NeutralINR 47.29B64.21―0.02%16.70%18.73%
IN:MOREPENLABIN:MOREPENLAB57NeutralINR 54.66B29.05―0.20%30.20%91.17%
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%
IN:ORCHPHARMAIN:ORCHPHARMA54NeutralINR 52.79B519.30――10.83%-89.83%
IN:UNICHEMLABIN:UNICHEMLAB51NeutralINR 35.07B10.39――6.44%283.10%
IN:INDOCOIN:INDOCO48NeutralINR 21.08B66.85―0.09%10.75%―

* General Sector Average

Performance Comparison

0%100%200%300%IN:GUFICBIOIN:BLISSGVSIN:INDOCOIN:MOREPENLABIN:ORCHPHARMAIN:UNICHEMLABDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
IN:GUFICBIO and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
IN:GUFICBIOGufic Biosciences Limited471.55156.8349.83%
IN:BLISSGVSBliss Gvs Pharma Limited673.00510.22313.45%
IN:INDOCOIndoco Remedies Limited228.30-32.27-12.39%
IN:MOREPENLABMorepen Laboratories Limited99.7553.60116.13%
IN:ORCHPHARMAOrchid Pharma Limited881.5023.552.74%
IN:UNICHEMLABUnichem Laboratories Limited498.0521.604.53%

Gufic Biosciences Limited Corporate Events

Gufic Biosciences Receives USFDA Observations After Pre-Approval Inspection at Indore Plant

Oct 23, 2026

Gufic Biosciences Limited has disclosed that the U.S. Food and Drug Administration recently conducted a pre-approval inspection at its manufacturing facility in Indore, Madhya Pradesh, over the period from October 15 to October 23, 2026. The inspecti...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Sep 30, 2026